Period of follow-up; strategy | % | Mean cost per patient (95% CI)†, $ | Cost difference (immediate treatment v. active surveillance) | |||
---|---|---|---|---|---|---|
Mortality* | Recurrence* | Discount* | Absolute, $ | Relative, % | ||
First year and 5-year follow-up | ||||||
Active surveillance | 3.8 | 13.9 | — | 6 200 (6 083–6 317) | 7 535 | 54.9 |
3.8 | 13.9 | 5 | 5 515 (5 413–5 619) | 7 551 | 57.8 | |
Immediate treatment | 3.8 | 2.57 | — | 13 735 (13 615–13 855) | ||
3.8 | 2.57 | 5 | 13 166 (12 966–13 165) | |||
First year and 10-year follow-up | ||||||
Active surveillance | 3.8 | 13.9 | — | 10 600 (10 377–10 822) | 7 808 | 42.4 |
3.8 | 13.9 | 5 | 8 484 (8 313–8 654) | 7 755 | 47.8 | |
Immediate treatment | 3.8 | 2.57 | — | 18 408 (18 162–18 653) | ||
3.8 | 2.57 | 5 | 16 239 (16 060–16 418) |
Note: CI = confidence interval. *Yearly rate. †The 95% CI of the mean cost was obtained by the simulation of 1000 samples of equal sample size of 12 750 patients.